Response to COVID-19 vaccination imaged by PD-L1 PET scanning

MacManus, MP; Akhurst, T; Lewin, SR; Hegi-Johnson, F

Author(s): MacManus, MP; Akhurst, T; Lewin, SR; Hegi-Johnson, F;
Details: Publication Year 2024-06-07,Volume 8,Issue #1,Page 16
Journal Title: EJNMMI Reports
Publication Type: Research article
Abstract: BACKGROUND: During a phase 0 clinical trial of an investigational programmed cell death ligand-1 (PD-L1) PET tracer in patients with non-small cell lung cancer (NSCLC), three patients received booster doses of COVID-19 vaccines before PD-L1 imaging. METHODS: Five patients underwent whole-body PET/CT imaging with a novel PD-L1 tracer, constructed by attaching (89)Zr to the anti PD-L1 antibody durvalumab. Intramuscular (deltoid) booster doses of mRNA BNT162b2 COVID-19 mRNA vaccine were coincidentally given to three patients in the month before PD-L1 tracer injection. RESULTS: Two recently-vaccinated patients, in remission of NSCLC and receiving non-immunosuppressive cancer therapies (immunotherapy and tyrosine kinase inhibitor respectively), showed increasing PD-L1 tracer uptake in ipsilateral axillary lymph nodes. No asymmetric nodal uptake was seen in a third recently-vaccinated patient who was receiving immunosuppressive chemotherapy, or in two patients not recently-vaccinated. CONCLUSION: Immune response to mRNA BNT162b2 vaccination may involve regulation by PD-L1 positive immune cells in local draining lymph nodes in immunocompetent patients. TRIAL REGISTRATION: This trial was registered with the Australian New Zealand Clinical Trials Registry. Registration number ACTRN12621000171819. Date of Trial Registration 8/2/2021. Date of enrolment of 1st patient 11/4/2021. URL of trial registry record: https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12621000171819 .
Publisher: Springer Nature
Keywords: Covid-19; Lung cancer; Pd-l1; Positron emission tomography; Vaccination
Department(s): Radiation Oncology; Cancer Imaging
Publisher's Version: https://doi.org/10.1186/s41824-024-00196-7
Open Access at Publisher's Site: https://doi.org/10.1186/s41824-024-00196-7
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-08-06 08:21:51

Last Modified: 2024-08-06 08:24:57